Propanc Biopharma, Inc. (PPCB) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Camberwell, VIC, Australia. The current CEO is James Nathanielsz.
PPCB has IPO date of 2012-11-12, 1 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $1.48M.
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
